Guggenheim Maintains Buy on AbbVie, Raises Price Target to $190
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan maintains a Buy rating on AbbVie (NYSE:ABBV) and raises the price target from $188 to $190.
March 22, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Vamil Divan maintains a Buy rating on AbbVie and raises the price target from $188 to $190.
The increase in price target by Guggenheim reflects a positive outlook on AbbVie's stock, suggesting potential upside. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100